REUTERS   by Kate Kell and Ben Herschler                                                                        Feb. 1. 2015
LONDON --As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast.

Determined not to lose scientific momentum that could make the world's first effective Ebola interventions a reality, researchers say the shots, as well as being proven to work, must be cheap, easy to handle in Africa and able to hit multiple virus strains.

That may mean shifting focus from the stripped-down, fast-tracked vaccine development ideas that have dominated the past six months, but it mustn't mean the field gets bogged down in complexities.

Read complete story.

Vaccine  was made by introducing an Ebola gene in a chimpanzee cold virus

THE VERGE    by Arielle Duhaime-Ross                                                             Jan. 28, 2015

An Ebola vaccine produced using a chimpanzee common cold virus appears to be safe to use on humans, according to a study published today in the New England Journal of Medicine. Three different doses of vaccine were tested on healthy humans in the UK, and it was well-tolerated; it triggered high levels of antibody formation without also triggering serious side effects. But until the vaccine is tested in an area where an Ebola risk actually exists, it’s efficacy against the disease will remain a mystery.

Read complete story.
http://www.theverge.com/2015/1/28/7930947/ebola-vaccine-human-trials-results

A Monovalent Chimpanzee Adenovirus Ebola Vaccine — Preliminary Report

 New England Journal of Medicine

NBC NEWS   by Maggie Fox                                                                      Jan. 14, 2015
Cup by cup, Emory University is collecting bags of liquid gold from the small club of American Ebola survivors.

They're collecting the plasma as part of an experiment to see if transfusing blood from people who have lived through the horrific infection can save the newly ill. Many of the survivors have been given this so-called convalescent plasma, but no one knows if it's actually helping.

"The protocol allows us to collect and transfuse convalescent plasma from U.S. Ebola survivors," says Dr. Anne Winkler, the Emory pathologist overseeing the study. "This is a completely voluntary process."